BRCA Mutations less risky than thought

Implications: New data indicates risk of invasive breast cancer in women with either BRCA mutation maybe less than previuosly thought This new information will adversely impact Myriad's business

Analysis: While the science of cancer heredity is far from complete, I feel it is a top concern to physicians as well as patients. The down grading of breast cancer risk from 40 -50% as opposed to 50-100% is not likely to give comfort to the women with the mutation, knowning thir chance of avoiding cancer is not much better than a coin toss. Also, many of the BRCA cancers are triple negative, which as particularly bad actor in regards to response to therpay. I feel companies like Myriad realize we need to pursue other hereditary factors in breast as well as other cancers which will likely lead to more $3000 test to offer.